{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(1)"],"submitter":["Gomez-Rosel M"],"pubmed_abstract":["Adoptive therapy with CAR-T cells and systemic administration of bispecific T-cell engagers (TCE) have achieved unprecedented success in the treatment of relapsed/refractory (R/R) B-cell malignancies. However, high relapse rates remain a major challenge. STAb (<b>S</b>ecretion of <b>T</b> cell-redirecting bispecific Antibodies)-T-cell immunotherapy represents a promising alternative by enabling both polyclonal T-cell recruitment and sustained bispecific antibody release. Here, we describe an evolution of STAb-T19 therapy, which has demonstrated superior outcomes to those of CAR-T-19 cells in preclinical models of B-ALL, on the basis of the simultaneous secretion of two bispecific antibodies: a CD19 × CD3 TCE and a PD-L1 × 4-1BB bsAb. The combined approach aims to increase the antitumor eff"],"journal":["Oncoimmunology"],"pagination":["2570224"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12562732"],"repository":["biostudies-literature"],"pubmed_title":["Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager."],"pmcid":["PMC12562732"],"pubmed_authors":["Gomez-Rosel M","Rubio-Perez L","Diez-Alonso L","Alvarez-Vallina L","Zagorac I","Hangiu O","Navarro R","Compte M","Blanco B","Torres-Ruiz R","Rodriguez-Perales S","Blanco FJ","Dominguez-Alonso C"],"additional_accession":[]},"is_claimable":false,"name":"Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager.","description":"Adoptive therapy with CAR-T cells and systemic administration of bispecific T-cell engagers (TCE) have achieved unprecedented success in the treatment of relapsed/refractory (R/R) B-cell malignancies. However, high relapse rates remain a major challenge. STAb (<b>S</b>ecretion of <b>T</b> cell-redirecting bispecific Antibodies)-T-cell immunotherapy represents a promising alternative by enabling both polyclonal T-cell recruitment and sustained bispecific antibody release. Here, we describe an evolution of STAb-T19 therapy, which has demonstrated superior outcomes to those of CAR-T-19 cells in preclinical models of B-ALL, on the basis of the simultaneous secretion of two bispecific antibodies: a CD19 × CD3 TCE and a PD-L1 × 4-1BB bsAb. The combined approach aims to increase the antitumor eff","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-05T09:22:32.558Z","creation":"2026-05-15T03:12:20.208Z"},"accession":"S-EPMC12562732","cross_references":{"pubmed":["41139953"],"doi":["10.1080/2162402X.2025.2570224"]}}